The state of Michigan currently has 410 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo.
Testing Experimental Anti-cancer Drug SLC-391 with an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers
NCT05860296
Recruiting
SLC-391 is a novel, potent and specific small molecule inhibitor of receptor tyrosine kinase AXL with desirable potency and pharmaceutical properties. The study is being done to evaluate the safety and pharmacokinetic (PK) profile of SLC-391 in combination with pembrolizumab in participants with non-small cell lung cancer (NSCLC). Each treatment cycle lasts 21 days. Participants will swallow SLC-391 pills two times every day. Participants will get pembrolizumab intravenously (IV) from the stud... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/14/2024
Locations: Karmanos Cancer Center, Detroit, Michigan
Conditions: Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic
Register for Updates
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
NCT05653752
Recruiting
This is a phase 1, multicenter, open-label, first-in-human study of YL202 conducted in the United States and China. The study will evaluate the safety and tolerability of YL202 in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated NSCLC or hormone receptor (HR)-positive and HER2-negative BC, which have been heavily treated by standard treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Non Small Cell Lung Cancer, Breast Cancer
Register for Updates
Intraoral Hypothermia Device for Preserving Taste During Radiation
NCT06579248
Recruiting
Radiation therapy to the head and neck region is known to cause taste dysfunction. Preliminary studies showed that cooling normal structures may lower damage caused by radiation. The purpose of this research study is to see if it is feasible to use an intraoral cooling device during radiation treatments to preserve or lower the decline of taste function.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2024
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Head and Neck Cancer, Taste Dysfunction, Radiation Therapy
Register for Updates
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors
NCT06136884
Recruiting
The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2024
Locations: Karmanos Cancer Institute, Detroit, Michigan
Conditions: Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, Endometrial Cancer
Register for Updates
Breast Cancer Resiliency Through Exercise Program (B-REP)
NCT06100263
Recruiting
The study will use a cross-sectional study design with a follow-up 2-arm randomized controlled trial with that has assessments at baseline, post-intervention (i.e., Week 12), and 3-months post-intervention (i.e., Week 24). The 2 arms are the 12-week intervention and a health education control among 60 Black breast cancer survivors.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/05/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Breast Cancer Female
Register for Updates
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT05254171
Recruiting
The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuvant or adjuvant treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
Register for Updates
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768
Recruiting
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be bette... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: Hickman Cancer Center, Adrian, Michigan +51 locations
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
Register for Updates
Interstitial Assessment of Architectural Heterogeneity in Prostate Cancer Using a Fine Needle Photoacoustic Probe
NCT05965180
Recruiting
In this project, we will integrate the Photoacoustic (PA) technology into a prostate biopsy procedure through a fine needle probe. The needle probe will be in the shape of a biopsy needle and compatible with the needle insertion mechanism in the transrectal ultrasound (TRUS) probe. When inserted into the prostate, the fine needle PA probe will assess the histological information in its surrounding tissue without any tissue extraction. The needle probe has been tested in prostate tissue samples a... Read More
Gender:
MALE
Ages:
Between 40 years and 80 years
Trial Updated:
10/29/2024
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Conditions: Prostate Cancer
Register for Updates
Building a Renewed ImaGe After Head & Neck Cancer Treatment (BRIGHT) Multi-Site RCT
NCT05442957
Recruiting
In this multi-center randomized clinical trial, head and neck cancer (HNC) survivors with clinically significant body image distress (BID) (N=180) will be randomized to BRIGHT (a brief video tele-cognitive behavioral therapy intervention) or Attention Control (AC, a manualized tele-supportive care intervention that controls for professional attention, dose, delivery method, and common factors). HNC survivors will complete IMAGE-HN (a validated patient-reported outcome measure \[PROM\] of HNC-rel... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/21/2024
Locations: Henry Ford Hospital, Detroit, Michigan
Conditions: Head and Neck Cancer, Body Image Disturbance, Body Image, Survivorship, Psychosocial Impairment, Mental Health Issue
Register for Updates
Ribociclib and Bicalutamide in AR+ TNBC
NCT03090165
Recruiting
This is an open label, multi-institutional, single arm phase II trial of ribociclib in combination with bicalutamide in advanced AR+ triple-negative breast cancer. No randomization or blinding is involved.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/10/2024
Locations: Michigan State University, Lansing, Michigan
Conditions: Triple Negative Breast Cancer
Register for Updates
A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
NCT05926765
Recruiting
This study will assess the efficacy and safety of bilateral intra-parotid administration of AAV2-hAQP1 in adults with Grade 2 or Grade 3 radiation-induced late xerostomia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: Henry Ford Health, Detroit, Michigan
Conditions: Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
Register for Updates
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NCT06334432
Recruiting
NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. In Phase 2, NUV-1511 will be given to determine the efficacy of patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/13/2024
Locations: Karmanos Cancer Center, Detroit, Michigan
Conditions: Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer, Platinum-resistant Ovarian Cancer (PROC)
Register for Updates